EyePoint Pharmaceuticals, Inc.
- EYPT
- NASDAQ
- Biotechnology
- Ophthalmic Drugs
- Sustained-Release Implants
- Eye Disease Treatments
$0.44
Today −85.38%Quote Oct 19, 2026, 05:00 PM UTC
−25.06%over the last month
Max drawdown −26.5%From 1-month high −26.5%3 months −76.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom.
Where the money comes from
Q3 2025 revenue $966,000
- Product$582,00060.2%
- Royalty$234,00024.2%
- License And Collaboration Agreement$150,00015.5%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
214
Founded
1987
Market value
$36.6M
Quote Oct 19
Resistance
$2.59
492.5% above price
Price vs analyst targets
20 analysts
Lowest target
$1.00Highest target
$40.00
$1.00Highest target
$40.00
- Price $0.44
- Average target $17.29
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 3856% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about EYPTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free